Michael L Shi

US Patent:

20130123272, May 16, 2013

Filed:

Apr 14, 2011

Appl. No.:

13/641668

Inventors:

Diana Graus Porta - Basel, CH
Herbert Schmid - Neuenburg, DE
Michael Shi - East Hanover NJ, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/496

US Classification:

51425307

Abstract:

The use of 4-amino-5-fluoro-3[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate for the manufacture of pharmaceutical compositions for use in the treatment of hepatocellular carcinoma or liver cancer.

US Patent:

20130345234, Dec 26, 2013

Filed:

Mar 15, 2012

Appl. No.:

14/003312

Inventors:

Humphrey Athelstan Roy Gardner - Salem MA, US
Michael Shi - Chalfont PA, US
Alejandro Yovine - Folgensbourg, FR

International Classification:

C12Q 1/68

US Classification:

51425307, 435 611

Abstract:

The present invention describes methods for diagnosing, treating and determining the prognosis of breast cancer HR+ patient, the methods including detecting the amplification of one or more biomarkers comprising a FGFR ligand such as FGF3, FGF4, FGF19, and/or a FGFR, such as for example FGFR1 in a subject; determining an FGFR1 inhibitor for treating the subject based on the amplification of the one or more biomarkers in the subject; administering to the subject in need thereof the FGFR1 inhibitor and using the one or more biomarkers to indicate prognosis of the subject treated with the FGFR1 inhibitor.

US Patent:

20130035343, Feb 7, 2013

Filed:

Apr 14, 2011

Appl. No.:

13/640585

Inventors:

Diana Graus Porta - Basel, CH
Michael Shi - East Hanover NJ, US
Dean Brent Evans - Therwil, CH

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/496
A61P 35/00

US Classification:

51425307

Abstract:

A pharmaceutical combination comprising 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one and at least one mTOR inhibitor and the pharmaceutical combination for use in treating or preventing a proliferative disease.

US Patent:

20230020548, Jan 19, 2023

Filed:

Oct 26, 2020

Appl. No.:

17/783019

Inventors:

- Basel, CH
Jiri Kovarik - Zürich, CH
Yue Li - Ettingen, CH
Elizabeth Akselrod McNamara - Salem MA, US
Karin Sigrid Meiser - Weil am Rhein, DE
Stephen John Oliver - Basel, CH
Michael Shi - Chalfont PA, US

International Classification:

C07K 16/24
A61P 7/00

Abstract:

This disclosure relates to use of anti-IL-1β antibodies (e.g., canakinumab or gevokizumab) in a therapy treating, preventing, reducing, or alleviating one or more manifestations and complications in individuals suffering from sickle cell disease (including, e.g., homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-tha1 gene, an individual with one sickle cell gene and one null allele, or an individual with hemoglobin sickle cell disease), optionally in combination with an additional therapeutic agent. Such manifestations and complications include, but are not limited to: pain, fatigue, hospitalization, poor sleep quality, work or school absences, narcotic use, acute or chronic blood transfusion therapy, acute chest syndrome, bone infarct, avascular necrosis, osteonecrosis, stroke, priapism, infarction of penis, a cardiovascular disorder, growth delay, stunted growth, low body mass index (BMI), low body weight, and organ damage.